Business Wire

Eyenuk Inc.’s AI-Based Diabetic Retinopathy Screening Software EyeArt™ Tested with Portable Smartphone-Based Imaging Device in New Study Indicating Potential for Highly Sensitive Yet Cost-Effective Mass Retinal Screening


Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence (AI) enabled solutions to identify diseases via retinal image analysis, today announced the publication of a study using Eyenuk’s EyeArt™ screening software on retinal images acquired with the Remidio Fundus on Phone (FOP) system, an FDA 510k registered fundus camera which combines a smartphone with patented optics. The study demonstrated very high sensitivity for detecting both any diabetic retinopathy (DR) and sight-threatening diabetic retinopathy (STDR), indicating potential for enabling highly sensitive yet cost-effective mass retinal screening.

The research, conducted at Madras Diabetes Research Foundation (MDRF) in Chennai, India, was published in the international ‘Eye’ journal (Springer Nature) by Dr. R. Rajalakshmi and her colleagues from MDRF. The study investigators chose Eyenuk’s EyeArt™ AI screening software to analyze retinal images of individuals with diabetes taken with a Remidio Fundus on Phone system. The EyeArt™ screening software results were compared to independent blinded grading by retinal specialists to evaluate the diagnostic efficacy. Sensitivity for detecting any DR and STDR was 95.8% and 99.1% respectively, while specificity was 80.2% and 80.4% respectively. The study authors noted that some non-DR retinal lesions like drusen, RPE atrophic patch, a retinal telangiectatic vessel at macula, RPE hypertrophy, tessellated fundus and retinal vein occlusion were the causes of false positives.

“We are very encouraged by this study demonstrating impressive sensitivity and specificity using EyeArt™ with images from this novel smartphone-based fundus imaging system. This is especially notable given that our AI system was never trained on images captured by the Remidio FOP system, suggesting the robustness and broad applicability of our software algorithms,” stated Kaushal Solanki, Founder & CEO of Eyenuk, Inc. “We look forward to converting these impressive results into real-world clinical practice by eventually making EyeArt™ available for mass diabetic retinopathy screening in conjunction with a lower-cost portable high-quality fundus imaging device like the Remidio system.”

According to the World Health Organization (WHO), there are nearly 285 million visually impaired people worldwide. As many as 80% of those cases could have been avoided with early detection. With 90% of those affected living in low-income areas, an effective, accessible, affordable, and easy-to-use screening system is critical for early detection of eye diseases such as diabetic retinopathy, which if untreated may lead to blindness. Combining EyeArt™ automated AI-based screening software with an affordable camera, such as the one offered by Remidio, may provide greater and less expensive access to eye screening around the world, and potentially reduce the incidence of blindness caused by diabetic retinopathy.

Until recently, diabetic retinopathy could only be detected by trained ophthalmologists and retina specialists who examine the back of the eye (retina) or by retinal color photography taken using expensive retinal cameras. Moreover, these retinal photographs had to be interpreted by trained eye doctors. Recently, advanced technologies like Remidio FOP that combine smartphones with sophisticated optics, have enabled cost-effective and high-quality retinal imaging that was not previously possible with basic smartphone attachments. Artificial intelligence, a simulation of intelligence by a software/machine, is a specialized field based on teaching the machine, via numerous examples, to accurately interpret the images. With recent advances in AI, pioneering tools like EyeArt™ can now be used to grade retinal images of people with diabetes to determine which patients have any retinopathy, or have sight-threatening retinopathy requiring urgent referral to an ophthalmologist.

Dr. V. Mohan, Chairman, Dr. Mohan’s Diabetes Specialities Centre and Director, MDRF said, “One out of 5 Indians with diabetes are at risk for developing diabetic retinopathy. Given the alarming increase in the number of people with diabetes and shortage of trained retinal specialists, computer-based analysis using artificial intelligence of the retinal photographs, taken using sleek and user-friendly smartphone-based cameras would reduce the burden of the health systems in screening for sight-threatening retinopathy. Use of artificial intelligence to analyze retinal images is a significant development and it fits in well with the current trend of using telemedicine to reach the remote underserved parts of the country especially the rural areas where specialized healthcare is often non-existent.”

Dr. R. Rajalakshmi, Head-Medical Retina, Dr. Mohan’s Diabetes Specialities Centre and MDRF said, “Regular retinal screening for all people with diabetes is still an unmet need in most countries especially in poor developing countries. Automated artificial intelligence software along with smartphone-based retinal imaging can be a promising initial tool for mass retinal screening.” She added that smartphone retinal color photography combined with an automated detection system can ideally result in models with potential for cost-effective routine clinical use by the primary care physicians.

Dr. Anand Sivaraman, CEO of Remidio Innovative Solutions Pvt. Ltd., said, “The simplicity achieved by combining smartphones with our patented optics has resulted in Remidio Fundus On Phone to be priced at 1/5th to 1/10th of any traditional desktop retinal imaging system, delivering high quality relevant images repeatedly with high sensitivity and specificity exceeding 92% and 98% when clinically validated. The use of artificial intelligence like EyeArt™ in screening the images from the Remidio Fundus on Phone device, now enables large scale public health screening for eye health among the 400 million affected by Diabetes, globally.”


Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and machine learning expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology combined with deep learning to identify and track the progression of diseases including diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular risk, and Alzheimer’s disease. EyeArt™ development was partially supported by prestigious National Eye Institute (NEI/NIH) grants (EB013585, EY026864, EY027241). EyeArt™ has received CE Marking and Health Canada approval, and is commercially available in the European Union and in Canada. In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale. For more information, visit


Madras Diabetes Research Foundation (MDRF), a unique 100% nonprofit research centre exclusively devoted for advanced research on diabetes and its complications, was established in 1996. Madras Diabetes Research Foundation is recognized by the Indian Council of Medical Research (ICMR) as “ICMR Centre for Advanced Research on Diabetes.”


Remidio is an innovative medical device company that seeks to create Healthcare Access by combining simplicity of product design with cutting edge technology and sustainable business model innovations. Remidio uses principles of Design Thinking and involves key stakeholders during the product development process – clinicians, patients, and health workers, with a view to designing product solutions that are simple to use, clinically relevant, reliable and scalable. Remidio’s CE marked and FDA 510k registered retinal imaging devices have helped screen and impact more than 7.5 million patients in 15 countries globally, as a result of increased access provided by the ease of use and affordability of Remidio’s patented optics on the smartphone platform.

Contact information

Eyenuk, Inc.
Kevin Skol, +1 (707) 702-3585
Dr. V. Mohan, +91 44- 4396 8888
Dr. R. Rajalakshmi, +91 44- 4396 8888
Dr. Anand Sivaraman, +91 9845155475

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 201822.3.2018 16:32Pressemelding

On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”. This press release features multimedia. View the full release here: MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire) After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website Further to this online momentum, MyKronoz has successfully shipped to over 10

Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing22.3.2018 14:59Pressemelding

Redwood Software, the pioneer behind ‘The Robotic Enterprise’, today announced the launch of a revolutionary new robotic licensing model, where customers only pay for the robotic services they consume within their business. Available now, this new licensing model allows customers to directly compare the costs of manual work against processes that are robotized. With the unique Robotic Service Charge, Redwood only charges for the delivery of a robotic service, equivalent to a unit of work that can done by a person (send an email, download a report, reconcile two reports etc.). Redwood delivers a catalogue of 35,000 of these ready built robotic services that can be linked together by business users in a visual plug and play interface. End-to-end business processes can be modelled, robotized, tested and deployed without cost and risk. Only when the robotic service is consumed is a charge made, always replacing work that would otherwise be done manually. Within the Robotic Service Charge,

German Chemical Major Covestro Awards L&T Technology Services Multi-Million Dollar ER&D Project22.3.2018 14:34Pressemelding

Germany’s Covestro, a world-leading manufacturer of high-tech polymer materials, has chosen L&T Technology Services Limited (NSE: LTTS), as one of its major engineering services partners to implement digitalization based Engineering Programs across Covestro’s global locations. L&T Technology Services, a global leading pureplay ER&D services company, has been awarded a multi-million dollar contract by Covestro to execute these engineering transformational programs. This press release features multimedia. View the full release here: (L to R) Amit Chadha, President Sales & Business Development and Member of the Board, LTTS, Ferry Feldbrugge, Head of Global Projects & Engineering and Global Technical Contracting, Covestro and Stephan Krebber, Program Director, OSI2020 Program, Covestro signing the Master Service Agreement for Digital Transformation and Global Standardization Programs (Photo: Business Wire) Covestro is running a digi

The Saga Foundation Announces Its Plan to Create a Non-Anonymous, Reserve-Backed Digital Currency22.3.2018 13:00Pressemelding

The Saga Foundation ( announces today its mission to create Saga (SGA), the first non-anonymous blockchain-based digital currency. The currency is designed with a tamed volatility mechanism. These characteristics can set the ground for the currency to become a store of value and a medium of exchange. Saga is designed to address legitimate concerns expressed by policy makers, regulators and market participants regarding cryptocurrencies; mainly their anonymity, lack of underlying value and high volatility. Saga holders must satisfy full KYC (Know Your Customer) qualification and AML (Anti Money Laundering) requirements under Swiss law. With such disclosures, Saga resolves concerns about participant accountability, an issue that is generally raised regarding cryptographic currencies. Saga aims to promote a low-volatility environment, combining the virtues of blockchain technologies with algorithmic representations of financial tools. For this reason, Saga is backed by a variable Celebrates the Launch of Their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party!22.3.2018 12:48Pressemelding

This evening, international etailer,, celebrated the launch of their newest Spring collection at an exclusive launch party in Los Angeles at The Dream Hollywood for media, influencers, and friends of the brand. This press release features multimedia. View the full release here: Celebrates the Launch of their Spring Collection & the Zendaya Edit with a 90s Throwback Block Party! Taking note from the product aesthetic, the event served as the ultimate 90s nostalgia trip with bright and bold décor from neon signs to giant boom boxes and life-size cassette tapes. Throughout the night, guests engaged in various activations including 90s dance lessons, cocktail making, cooking lessons, firework displays and interactive arcade games. Attendees also enjoyed 90s-inspired catering including retro treats Bubble Tape and Candy Necklaces, as well as Slush Puppies and Sunny D cocktails. Surprise musical guests, Snoop Dog

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood22.3.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) were published in Blood . The manuscript is available online today and will be included in a future print edition of Blood. The final five-year results support ICLUSIG as an effective treatment option for patients with chronic-phase CML (CP-CML) whose prior therapies have failed. ICLUSIG, a tyrosine kinase inhibitor (TKI) with potent activity against native and mutant forms of BCR-ABL1 (an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL), received full approval from the U.S. Food and Drug Administration in 2016. ICLUSIG is indicated for the treatment of adult patients with CML or Ph+ ALL for whom no other TKI is indicated, including those with T315I-positive CML or T315I-positive Ph+ ALL. ICLUSIG is not ind